Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 20/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 14,95,399 | 0.8208% | ||
| 01/08/24 | Issuer sale | Director | 1,08,985 | 0.0598% | ||
| 01/08/24 | Issuer sale | Director | 1,37,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 819.15Cr | |
| -2.43% | -7.34% | +36.10% | +58.44% | 6.22TCr | |
| +0.59% | +0.72% | +11.07% | +69.33% | 5.49TCr | |
| +0.43% | +2.49% | +20.85% | +97.99% | 5.53TCr | |
| +1.26% | -3.47% | +22.56% | +32.93% | 4.26TCr | |
| -1.61% | -2.81% | +14.08% | +93.58% | 4.11TCr | |
| +3.71% | +4.81% | +228.97% | +780.76% | 4.03TCr | |
| +0.57% | +23.82% | +99.03% | +83.71% | 3.31TCr | |
| +0.21% | +1.05% | +14.81% | +46.96% | 3.26TCr | |
| -2.92% | +12.57% | -42.60% | +330.18% | 2.4TCr | |
| Average | +0.05% | +3.94% | +44.99% | +177.10% | 4.29TCr | |
| Weighted average by Cap. | -0.00% | +2.26% | +45.38% | +160.10% |
Employees
355
